clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kanayama N et al. | Drug-drug interactions in the metabolism of imidafenacin: role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. | 2007 | Xenobiotica | pmid:17484517 |
| Altintas E et al. | Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. | 2004 | World J. Gastroenterol. | pmid:15162544 |
| Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
| Choi HS et al. | Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. | 2012 | World J. Gastroenterol. | pmid:22654429 |
| Si JM et al. | Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. | 2005 | World J. Gastroenterol. | pmid:15948255 |
| Hagiwara T et al. | Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. | 2007 | World J. Gastroenterol. | pmid:17657838 |
| Kawakami E et al. | Furazolidone-based triple therapy for H pylori gastritis in children. | 2006 | World J. Gastroenterol. | pmid:17006997 |
| Sanches BS et al. | Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. | 2016 | World J. Gastroenterol. | pmid:27672279 |
| Gumurdulu Y et al. | Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. | 2004 | World J. Gastroenterol. | pmid:14991935 |
| Ahmad N et al. | Characterization of clarithromycin resistance in Malaysian isolates of Helicobacter pylori. | 2009 | World J. Gastroenterol. | pmid:19575497 |
| Guo CY et al. | Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. | 2004 | World J. Gastroenterol. | pmid:14991953 |
| Mirbagheri SA et al. | Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. | 2006 | World J. Gastroenterol. | pmid:16937475 |
| Luo XF et al. | Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori. | 2016 | World J. Gastroenterol. | pmid:27433095 |
| Ching SS et al. | Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. | 2008 | World J. Gastroenterol. | pmid:18609709 |
| Miehlke S et al. | Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). | 2001 | World J. Gastroenterol. | pmid:11819768 |
| Trifan A et al. | Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. | 2013 | World J. Gastroenterol. | pmid:24259981 |
| Sun QJ et al. | Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. | 2010 | World J. Gastroenterol. | pmid:20976850 |
| Chuah SK et al. | A new look at anti-Helicobacter pylori therapy. | 2011 | World J. Gastroenterol. | pmid:22046084 |
| Matta AJ et al. | Punctual mutations in gene of clarithromycin-resistant in Colombian populations. | 2018 | World J. Gastroenterol. | pmid:29662291 |
| Buzás GM and Józan J | First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. | 2006 | World J. Gastroenterol. | pmid:16981260 |
| Chen SJ et al. | Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients. | 2008 | World J. Gastroenterol. | pmid:18350632 |
| Sargýn M et al. | Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. | 2003 | World J. Gastroenterol. | pmid:12717872 |
| Abadi ATB | Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. | 2017 | World J. Gastroenterol. | pmid:29085187 |
| Lai YC et al. | Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. | 2004 | World J. Gastroenterol. | pmid:15052680 |
| Ji F et al. | Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. | 2006 | World J. Gastroenterol. | pmid:16586550 |
| Molina-Infante J and Gisbert JP | Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. | 2014 | World J. Gastroenterol. | pmid:25132750 |
| Cianci R et al. | Third-line rescue therapy for Helicobacter pylori infection. | 2006 | World J. Gastroenterol. | pmid:16688818 |
| Sereni G et al. | Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. | 2012 | World J. Gastroenterol. | pmid:22969227 |
| Isomoto H et al. | Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15786539 |
| Wang HH et al. | One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. | 2005 | World J. Gastroenterol. | pmid:15786549 |
| Aydemir S et al. | Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. | 2005 | World J. Gastroenterol. | pmid:15682477 |
| O'Morain C | Role of Helicobacter pylori in functional dyspepsia. | 2006 | World J. Gastroenterol. | pmid:16718752 |
| Shimbo I et al. | Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. | 2005 | World J. Gastroenterol. | pmid:16437727 |
| Wang CH et al. | Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. | 2015 | World J. Gastroenterol. | pmid:26494972 |
| Sugimoto M and Furuta T | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. | 2014 | World J. Gastroenterol. | pmid:24914361 |
| Heo J and Jeon SW | Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. | 2014 | World J. Gastroenterol. | pmid:24914324 |
| Sun WH et al. | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. | 2005 | World J. Gastroenterol. | pmid:15832421 |
| Wu IT et al. | Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. | 2015 | World J. Gastroenterol. | pmid:26457027 |
| Yilmaz O and Demiray E | Clinical role and importance of fluorescence in situ hybridization method in diagnosis of H pylori infection and determination of clarithromycin resistance in H pylori eradication therapy. | 2007 | World J. Gastroenterol. | pmid:17278188 |
| Zhao LJ et al. | Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. | 2014 | World J. Gastroenterol. | pmid:24782630 |
| Mohammadi M et al. | Helicobacter pylori antibiotic resistance in Iran. | 2005 | World J. Gastroenterol. | pmid:16273615 |
| Nishida T et al. | Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. | 2014 | World J. Gastroenterol. | pmid:24764674 |
| Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
| Onyekwere CA et al. | Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. | 2014 | World J. Gastroenterol. | pmid:24707145 |
| Wu JY et al. | Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. | 2014 | World J. Gastroenterol. | pmid:24695835 |
| Gao XZ et al. | Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. | 2010 | World J. Gastroenterol. | pmid:20818821 |
| Mabe K et al. | Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? | 2009 | World J. Gastroenterol. | pmid:19750572 |
| Farshad S et al. | Antimicrobial susceptibility of Helicobacter pylori strains isolated from patients in Shiraz, Southern Iran. | 2010 | World J. Gastroenterol. | pmid:21128326 |
| Riquelme A et al. | Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. | 2007 | World J. Gastroenterol. | pmid:17589948 |
| Ersoy O et al. | H pylori infection in patients with Behcet's disease. | 2007 | World J. Gastroenterol. | pmid:17589951 |